Journal: Molecular Medicine Reports
Article Title: Stigmasterol exerts antiglioma effects by regulating lipid metabolism
doi: 10.3892/mmr.2024.13351
Figure Lengend Snippet: Construction and validation of a prognostic model associated with stigmasterol target genes. (A) Venn diagram of potential targets of stigmasterol in the treatment of GBM, prognosis-related genes of patients with GBM and lipid metabolism-related genes. (B) Two prognosis-related target mRNAs of stigmasterol for GBM treatment were selected. (C and D) Least absolute shrinkage and selection operator variable screening process. (E) Distribution of survival status and risk score of patients with GBM in the training set. (F) Expression characteristics of the two prognosis-related target mRNAs of stigmasterol for GBM treatment in the training set. (G) ROC curve for patient survival of the training set. (H) Survival analysis between the two risk subgroups in the training set. (I) ROC curve for patient survival of the internal validation set. (J) Survival analysis between the two risk subgroups in the internal validation set. (K) ROC curve for patient survival of the external validation set. (L) Survival analysis between the two risk subgroups in the external validation set. GBM, glioblastoma; ROC, receiver operating characteristic; FABP5, fatty acid binding protein 5; ADRA1B, α-1B adrenergic receptor; AUC, area under the curve.
Article Snippet: For detection, the following secondary antibodies were used: HRP-conjugated goat anti-rabbit immunoglobulin G (IgG) antibody (dilution, 1:5,000; cat. no. A0208; Beyotime Institute of Biotechnology) for FABP5 and ADRA1B detection, and HRP-conjugated goat anti-mouse IgG antibody (dilution, 1:5,000, cat. no. SA00001-1; Proteintech Group, Inc.) for β-actin detection.
Techniques: Selection, Expressing, Binding Assay